Focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer    


Igenica Biotherapeutics was focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The company wound down operations in late 2017.


Year Invested: 2012
Location: Burlingame, Calif.